November 30, 2021

Beyond Going Long

Complete UK News World

In the UK, people between the ages of 40 and 49 get the third dose of the vaccine

In the UK, people between the ages of 40 and 49 get the third dose of the vaccine

Britain is trying to boost the weakened immune system of people before the cold winter months.

London. Administration of a booster dose Vaccines It will be extended to people between the ages of 40 and 49 in Britain, officials there said on Monday. They try to boost the weakened immune system of people before the cold winter months. Reuters news agency reported.

Currently, people 50 years of age and older, vulnerable individuals and leading health professionals are entitled to a booster dose of the vaccine. The Joint Vaccine and Immunization Committee (JCVI) has now announced that the booster (third) dose will be extended to another group.

The recommendation comes at a time when practical data show that the booster dose of the vaccine provides more than 90% protection against symptomatic disease. COVID-19 50 years and older.

Related article The United Kingdom has conditionally approved Merck’s anti-govt pill According to

“Strengthening benefits for the most vulnerable adults and second benefits for young people between the ages of 16 and 17 are an important way to enhance our defense against goiter and serious illnesses,” said the JCVI President. Govt vaccine Wei Shen Lim.

“These benefits will help extend our security until 2022,” he added. The UK booster vaccine uses vaccines from Pfizer / BioNTech and Moderna, and people can get a third dose six months after the second dose.

Practical study shows that protection against symptomatic disease after a booster dose is 93.1 percent in those who received the first estrogen vaccine and 94 percent in those who received the Pfizer vaccine earlier. JCVI added that greater protection against the acute course of the disease is expected after the booster dose.

See also  Bosnia's international defender Srebrenica has been banned from denying genocide

However, the team refused to recommend booster doses for people under the age of 40 because the researchers did not find significant evidence of a decrease in cov- eral safety after the original doses were given to this age group.